Page 82 - 南京医科大学学报自然科学版
P. 82

南京医科大学学报(自然科学版)                                  第42卷第7期
               ·978 ·                     Journal of Nanjing Medical University(Natural Sciences)   2022年7月


             ·基础研究·

              肿瘤患者头孢哌酮和美罗培南药物抗体阳性率及影响因素分析



              邵树军 ,祁      欣 ,桂佳林 ,高        明 ,陈玉平 ,王兰菊       1
                                             2
                             1
                                     1
                     1
                                                     2
               郑州大学附属肿瘤医院(河南省肿瘤医院)输血科,河南                    郑州    450008;江苏力博医药生物技术股份有限公司,江苏                 江
              1                                                         2
              阴 214400
             [摘    要] 目的:探讨头孢哌酮和美罗培南在肿瘤患者中药物抗体产生情况及与患者疾病、性别、年龄等因素的关系,为抗生
              素合理用药和精准医疗提供依据。方法:采用微柱凝胶法检测501例肿瘤患者使用头孢哌酮和美罗培南后药物抗体的产生情
              况,并分析其影响因素。结果:肿瘤患者头孢哌酮药物抗体阳性率为 30.54%(124/406),美罗培南药物抗体阳性率为 40.00%
             (38/95);头孢哌酮和美罗培南药物抗体阳性患者以血液系统肿瘤为主,阳性率分别为36.43%和40.96%;不同年龄分组的检测
              结果表明,31~40 岁组的头孢哌酮药物抗体阳性率最高,达到 70.37%,41~50 岁组美罗培南药物抗体阳性率最高,达到
              86.67%。结论:肿瘤患者使用头孢哌酮及美罗培南后可诱导机体产生药物抗体,药物抗体的产生与疾病、性别、年龄等因素
              相关。
             [关键词] 肿瘤;头孢哌酮;美罗培南;药物抗体
             [中图分类号] R979.1                    [文献标志码] A                       [文章编号] 1007⁃4368(2022)07⁃978⁃05
              doi:10.7655/NYDXBNS20220710


              Drug antibody positive rates of cefoperazone and meropenem and influencing factors in

              tumor patients
                                           1
                                 1
                          1
                                                      2
                                                                   2
              SHAO Shujun ,QI Xin ,GUI Jialin ,GAO Ming ,CHEN Yuping ,WANG Lanju 1
              1 Department of Transfusion,the Affiliated Cancer Hospital of Zhengzhou University,Henan Cancer Hospital,
              Zhengzhou 450008;Jiangsu LIBO Medicine Biotechnology Co.,Ltd,Jiangyin 214400,China
                               2
             [Abstract] Objective:To investigate the production of drug antibodies in tumor patients treated with cefoperazone and meropenem,
              and to provide the basis for rational use of antibiotics and accurate medical treatment. Methods:Microcolumn gel method was used to
              detect the production of antibodies in 501 cases of tumor patients after using cefoperazone and meropenem,and influencing factors
              were analyzed. Results:The positive rate of cefoperazone drug antibody in tumor patients was 30.54%(124/406),and the positive rate
              of meropenem drug antibody was 40.00%(38/95). The cefoperazone and meropenem drug antibody were mainly detected in patients
              with blood system diseases,of which the positive rates was 36.43% and 40.96% respectively. The results of different age groups showed
              that the positive rate of cefoperazone drug antibody was the highest in 31~40 years old group,reaching 70.37%. The positive rate of
              meropenem drug antibody was the highest in 41~50 years old group,reaching 86.67% . Conclusion:The use of cefoperazone and
              meropenem in tumor patients could induce drug antibodies and the production of drug antibodies is related to disease,gender,and age.
             [Key words] tumor;cefoperazone;meropenem;drug antibody
                                                                            [J Nanjing Med Univ,2022,42(07):978⁃982]





                  近年来随着抗生素的广泛使用,治疗过程中患                          或误诊,延误治疗可能发生器官损伤,严重者可致
              者容易产生药物抗体,从而诱发药物诱导的免疫溶                            生命危险 。头孢哌酮为第三代头孢菌素,是经典
                                                                         [1]
              血性贫血(drug⁃induced immune hemolytic anemia,        的β⁃内酰胺类抗生素,美罗培南为碳青霉烯类抗生
              DIIHA)。DIIHA 的发病率虽然较低,但其临床表现                      素,是非典型的β⁃内酰胺类抗生素,具有耐酶性、广
                                                                                           [2]
              多样,不易与其他类型溶血性贫血鉴别,容易漏诊                            谱性、高效性和低毒性等优点 。虽然头孢哌酮和
   77   78   79   80   81   82   83   84   85   86   87